John C. Dawson

This study screens a large compound library across patient-derived GBM stem cells to identify effective drugs targeting tumor heterogeneity and presents validated hits for further exploration.

This paper shows that FAK inhibition remodels the metastatic ECM, enhancing CD8+ T cell infiltration and immunosurveillance in breast cancer.

This study identifies three compounds targeting glioblastoma stem cells using machine learning and high-throughput screening of patient-derived models.

This study shows FAK regulates glycolysis and glutamine oxidation in glioblastoma stem cells, affecting mitochondrial morphology and cell migration.

This paper identifies Flunarizine as a compound that inhibits radiation-induced astrocyte reactivity and improves survival in a glioblastoma model.

This study identifies a synergistic combination of FAK and MEK inhibitors that effectively targets glioblastoma heterogeneity and improves therapeutic outcomes.

This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.

The paper uses cell painting to identify drugs that reverse SORL1 deletion phenotypes in neural progenitor cells, revealing potential therapeutic targets for Alzheimer's disease.

The paper develops a high-content screen to identify inhibitors of mitochondrial DNA maintenance in trypanosomes and identifies a novel kDNA-targeting compound.

This study shows that Trichoplein regulates endothelial cell function by controlling autophagy, with implications for vascular health and coronary artery disease.